ALX Oncology Announces Initial Data from ASPEN-02, the Ongoing Phase 1 / 2 Study of Evorpacept in Combination with Azacitidine, Demonstrating Safety and Preliminary Activity in Patients with Myelodysplastic Syndrome

Stacey Gandler
Brand Nourishment

Joey Cohen
Medication Adherence

Paul Theisen
Patient Acquisition

Bud Bilanich
Success Coach

Pat Purcell
Meeting Engagement

Liz Kane
Impactful Strategy

Frank Burrell
Scientific Storytelling

Matt Turner
Patient Affordability

Brenda Snow
Authentic Patient Voice

David Linetsky
Point-of-Care Marketing

Matthew Durham
Omnidynamic Marketing

Amy Giles
Increasing Engagement

Suma Ramadas, PhD
Medical Affairs

Daniel Sontupe
Market Access